Research Use Only - Important Disclaimer
All products listed on this website are intended for laboratory research use only and are not for human consumption, medical, veterinary, or household use. These products should only be handled by qualified professionals. We do not provide any dosage information, and the products must not be used as food additives, drugs, cosmetics, or for any other inappropriate applications. By purchasing, you acknowledge and agree to these terms.
Cagrisema Sodium
Peptide Compound for Metabolic Research
Cagrisema is a co-formulation of cagrilintide and semaglutide, combining the effects of amylin and GLP-1 receptor agonism for enhanced weight loss and glycemic control.
Usage:
Used in research on obesity, appetite regulation, and glucose metabolism. Promising results in weight loss and Type 2 diabetes models.
Mechanism of Action:
Combines GLP-1 receptor activation with amylin receptor activity to suppress appetite, slow gastric emptying, and improve metabolic parameters.
Benefits:
- Appetite suppression
- Weight reduction
- Improved glucose control
- Delayed gastric emptying
Side Effects:
- Nausea
- Constipation
- Loss of appetite
- Mild gastrointestinal discomfort
Suggested Dosage:
Not specified
Half-life: 5–7 days (approximate)
Delivery: Subcutaneous injection